1.6350
0.0000
(0.00%)
At close: January 9 at 7:00:00 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
16,245.0000
25,375.0000
17,501.0000
12,415.0000
5,479.0000
Cost of Revenue
8,971.0000
10,318.0000
10,880.0000
7,456.0000
3,762.0000
Gross Profit
7,274.0000
15,057.0000
6,621.0000
4,959.0000
1,717.0000
Operating Expense
65,589.0000
64,661.0000
55,214.0000
50,773.0000
37,564.0000
Operating Income
-58,315.0000
-49,604.0000
-48,593.0000
-45,814.0000
-35,847.0000
Net Non Operating Interest Income Expense
-5,497.0000
1,412.0000
179.0000
2.0000
113.0000
Other Income Expense
--
-2,118.0000
1,046.0000
-44.0000
-307.0000
Pretax Income
-65,930.0000
-50,310.0000
-47,368.0000
-45,856.0000
-36,041.0000
Tax Provision
-7,068.0000
-7,043.0000
-6,879.0000
-6,446.0000
-3,494.0000
Net Income Common Stockholders
-58,862.0000
-43,267.0000
-40,489.0000
-39,410.0000
-32,547.0000
Diluted NI Available to Com Stockholders
-58,862.0000
-43,267.0000
-40,489.0000
-39,410.0000
-32,547.0000
Basic EPS
-0.45
-0.39
-0.42
-0.44
-0.40
Diluted EPS
-0.45
-0.39
-0.42
-0.44
-0.40
Basic Average Shares
132,522.0790
111,277.2500
96,584.5120
88,950.4410
81,776.3810
Diluted Average Shares
132,522.0790
111,277.2500
96,584.5120
88,950.4410
81,776.3810
Total Operating Income as Reported
-58,315.0000
-49,604.0000
-48,593.0000
-45,814.0000
-35,847.0000
Rent Expense Supplemental
--
--
410.0000
332.0000
347.0000
Total Expenses
74,560.0000
74,979.0000
66,094.0000
58,229.0000
41,326.0000
Net Income from Continuing & Discontinued Operation
-58,862.0000
-43,267.0000
-40,489.0000
-39,410.0000
-32,547.0000
Normalized Income
-56,971.0594
-41,445.5032
-41,383.0950
-39,372.1851
-32,269.7622
Interest Income
3,067.0000
1,446.0000
226.0000
10.0000
129.0000
Interest Expense
8,564.0000
34.0000
47.0000
8.0000
16.0000
Net Interest Income
-5,497.0000
1,412.0000
179.0000
2.0000
113.0000
EBIT
-57,366.0000
-50,276.0000
-47,321.0000
-45,848.0000
-36,025.0000
EBITDA
-56,891.0000
-49,778.0000
-46,839.0000
-45,421.0000
-35,529.0000
Reconciled Cost of Revenue
8,971.0000
10,318.0000
10,880.0000
7,456.0000
3,762.0000
Reconciled Depreciation
475.0000
498.0000
482.0000
427.0000
496.0000
Net Income from Continuing Operation Net Minority Interest
-58,862.0000
-43,267.0000
-40,489.0000
-39,410.0000
-32,547.0000
Total Unusual Items Excluding Goodwill
-2,118.0000
-2,118.0000
1,046.0000
-44.0000
-307.0000
Total Unusual Items
-2,118.0000
-2,118.0000
1,046.0000
-44.0000
-307.0000
Normalized EBITDA
-54,773.0000
-47,660.0000
-47,885.0000
-45,377.0000
-35,222.0000
Tax Rate for Calcs
0.0001
0.0001
0.0001
0.0001
0.0001
Tax Effect of Unusual Items
-227.0594
-296.5032
151.9050
-6.1851
-29.7622
12/31/2020 - 9/25/2012
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ROQ.L Roquefort Therapeutics plc
3.6500
-9.88%
OBI.L Ondine Biomedical Inc.
9.00
0.00%
OBD.L Oxford BioDynamics Plc
0.9110
-8.90%
CRGX CARGO Therapeutics, Inc.
13.50
-4.93%
PSTX Poseida Therapeutics, Inc.
9.50
0.00%
BPTH Bio-Path Holdings, Inc.
0.9500
-2.92%
ATYR aTyr Pharma, Inc.
3.5300
-5.61%
ALNY Alnylam Pharmaceuticals, Inc.
237.98
-1.07%
CMRX Chimerix, Inc.
3.2500
-6.88%
ALLO Allogene Therapeutics, Inc.
2.0550
-12.55%